Mental Health Research Accelerator Act of 2025

1) WHAT HAPPENED: Representative Mike Thompson (D-CA) introduced HR2085, the Mental Health Research Accelerator Act of 2025, on March 11, 2025. The bill was referred to the House Committee on Ways and Means, where it remains without further action. It has 7 cosponsors. The bill proposes adding Section 45BB to the Internal Revenue Code, creating a 25% tax credit for translational research expenses on neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) and psychiatric conditions (e.g., depression, PTSD, anxiety). 2) MONEY TRAIL: This is a tax credit bill — it does NOT authorize or appropriate federal spending. Instead, it reduces the tax liability of companies that conduct qualifying research. The aggregate national cap is $1B for 2026, rising to $2B annually for 2027-2030, then back to $1B for 2031. Credits are allocated via competitive application by the Treasury Secretary in consultation with HHS, FDA, and NIH. Credits can be carried over if the annual cap is not fully subscribed. 3) STRUCTURAL WINNERS: Pure-play clinical-stage biotech companies focused on psychiatric conditions — $CMPS, $GHRS, $ATAI — are the most structurally positioned to benefit. These companies have no approved products and thus no taxable income; they cannot utilize tax credits directly unless they can carry them forward or monetize them (e.g., through transferability provisions, which are not specified in the bill). The credit's utility is contingent on future profitability or a transfer market. Large pharmaceutical companies with taxable income (e.g., $PFE, $MRK, $LLY, $JNJ) would be the most capable of using the credit immediately, but the $1B aggregate cap is small relative to their R&D budgets. 4) RECENT PRICE ACTION: Over the past 30 days, $CMPS has surged +51.54%, $GHRS +38.19%, and $ATAI +14.97%, largely driven by the April 18 Executive Order on psychedelic therapies. The 7-day trends are negative across the board (-12.53%, -4.05%, -12.1%), suggesting a pullback from post-Executive Order highs. $CMPS at $8.38 is near its 52-week high of $10.21; $GHRS at $19.43 is below its $24.66 high; $ATAI at $4.07 is below its $6.75 high. The market has already repriced on regulatory momentum, but the tax credit bill is distinct and early-stage. 5) TIMELINE: HR2085 requires passage by the House Ways and Means Committee, the full House, the Senate (either identical or via amendment), and either reconciliation or a standalone vote. As an early-stage bill with a partisan sponsor (D-CA) and a fiscal cost (tax credit), its path is long and uncertain. The 119th Congress runs through January 2027; if the bill does not advance to markup this year, it will likely not pass. The April 18 Executive Order does not change the bill's legislative status.